310 related articles for article (PubMed ID: 17082181)
1. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
[TBL] [Abstract][Full Text] [Related]
2. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
[TBL] [Abstract][Full Text] [Related]
3. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
4. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers.
Doody JF; Wang Y; Patel SN; Joynes C; Lee SP; Gerlak J; Rolser RL; Li Y; Steiner P; Bassi R; Hicklin DJ; Hadari YR
Mol Cancer Ther; 2007 Oct; 6(10):2642-51. PubMed ID: 17913857
[TBL] [Abstract][Full Text] [Related]
6. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
Kim HP; Han SW; Kim SH; Im SA; Oh DY; Bang YJ; Kim TY
Mol Cancer Ther; 2008 Mar; 7(3):607-15. PubMed ID: 18347147
[TBL] [Abstract][Full Text] [Related]
7. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
8. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
[TBL] [Abstract][Full Text] [Related]
10. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
[TBL] [Abstract][Full Text] [Related]
11. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.
Lu Y; Liang K; Li X; Fan Z
Mol Cancer; 2007 Oct; 6():63. PubMed ID: 17931419
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
Morelli MP; Cascone T; Troiani T; Tuccillo C; Bianco R; Normanno N; Romano M; Veneziani BM; Fontanini G; Eckhardt SG; De Pacido S; Tortora G; Ciardiello F
J Cell Physiol; 2006 Aug; 208(2):344-53. PubMed ID: 16688779
[TBL] [Abstract][Full Text] [Related]
14. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
[No Abstract] [Full Text] [Related]
15. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
[TBL] [Abstract][Full Text] [Related]
16. [Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].
Wang M; Zhang L; Zhao X; Liu J; Chen Y; Wang C
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):651-6. PubMed ID: 25564053
[TBL] [Abstract][Full Text] [Related]
17. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
19. Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations.
Peipp M; Schneider-Merck T; Dechant M; Beyer T; Lammerts van Bueren JJ; Bleeker WK; Parren PW; van de Winkel JG; Valerius T
J Immunol; 2008 Mar; 180(6):4338-45. PubMed ID: 18322248
[TBL] [Abstract][Full Text] [Related]
20. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo.
Hsu YF; Ajona D; Corrales L; Lopez-Picazo JM; Gurpide A; Montuenga LM; Pio R
Mol Cancer; 2010 Jun; 9():139. PubMed ID: 20529262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]